Core Viewpoint - Wan Jia Group (00401) reported a loss attributable to shareholders of HKD 712,000 for the six months ending September 30, 2025, despite a revenue increase of 2.4% to HKD 85.706 million, driven by growth in the blood dialysis business [1] Financial Performance - Revenue for the period was HKD 85.706 million, reflecting a year-on-year increase of 2.4% [1] - The company recorded a loss attributable to shareholders of HKD 712,000, compared to a profit of HKD 1.256 million in the same period last year [1] - Basic loss per share was HKD 0.127 [1] Business Segment Analysis - The increase in revenue was primarily driven by the growth in the blood dialysis business [1]

Core Points - The company reported a revenue of HKD 85.706 million for the six months ending September 30, 2025, representing a year-on-year increase of 2.4% [1] - The company recorded a loss attributable to shareholders of HKD 0.712 million, compared to a profit of HKD 1.256 million in the same period last year [1] - The basic loss per share was HKD 0.127 [1] - The increase in revenue was driven by the growth in the blood dialysis business [1]

Group 1 - The core point of the article is that Wan Jia Group (00401.HK) reported a revenue of approximately HKD 85.706 million for the six months ending September 30, 2025, representing an increase of about 2.40% compared to the same period in 2024, primarily due to increased revenue from its dialysis business [1] - The company reported a loss attributable to shareholders of approximately HKD 712,000 for the period, compared to a profit of approximately HKD 1.256 million in 2024 [1] - The basic and diluted loss per share for the period was approximately HKD 0.127 [1]